The Value of Cell-free Circulating Tumour DNA Profiling in Advanced Non-small Cell Lung Cancer (NSCLC) Management

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2021 Dec 17

PMID 34915883

Citations 6

Authors

Maria Gabriela O Fernandes

Natalia Cruz-Martins

Jose Carlos Machado

Jose Luis Costa

Venceslau Hespanhol

Affiliations

Soon will be listed here.

Abstract

Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients.

Citing Articles

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era.

Costa J, Membrino A, Zanchetta C, Rizzato S, Cortiula F, Rossetto C Int J Mol Sci. 2025; 25(24.

PMID: 39769431 PMC: 11727717. DOI: 10.3390/ijms252413669.

Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.

Ont Health Technol Assess Ser. 2024; 24(8):1-306.

PMID: 39698418 PMC: 11650780.

Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.

Wiegmans A, Ivanova E, Naei V, Monkman J, Fletcher J, Mullally W Clin Exp Metastasis. 2024; 41(3):219-228.

PMID: 38416302 PMC: 11213738. DOI: 10.1007/s10585-024-10270-w.

Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies.

Martin-Alonso C, Tabrizi S, Xiong K, Blewett T, Sridhar S, Crnjac A Science. 2024; 383(6680):eadf2341.

PMID: 38236959 PMC: 11529396. DOI: 10.1126/science.adf2341.

Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.

Iams W, Konduri K Adv Ther. 2023; 40(12):5567-5578.

PMID: 37779172 PMC: 10611827. DOI: 10.1007/s12325-023-02664-1.

References

Junqueira-Neto S, Batista I, Costa J, Melo S . Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA. Acta Cytol. 2019; 63(6):479-488. DOI: 10.1159/000493969. View

Fernandes M, Cruz-Martins N, Moura C, Guimaraes S, Pereira Reis J, Justino A . Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer. Cancers (Basel). 2021; 13(11). PMC: 8199488. DOI: 10.3390/cancers13112707. View

Douillard J, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G . Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9):1345-53. PMC: 4224589. DOI: 10.1097/JTO.0000000000000263. View

Uozu S, Imaizumi K, Yamaguchi T, Goto Y, Kawada K, Minezawa T . Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies. BMC Pulm Med. 2017; 17(1):175. PMC: 5719748. DOI: 10.1186/s12890-017-0514-3. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Rolfo C, Cardona A, Cristofanilli M, Paz-Ares L, Diaz Mochon J, Duran I . Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 2020; 151:102978. DOI: 10.1016/j.critrevonc.2020.102978. View

Fernandes M, Sousa C, Pereira Reis J, Cruz-Martins N, Moura C, Guimaraes S . Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic. Cells. 2021; 10(8). PMC: 8394732. DOI: 10.3390/cells10081912. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

10.

Schrock A, Welsh A, Chung J, Pavlick D, Bernicker E, Creelan B . Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018; 14(2):255-264. DOI: 10.1016/j.jtho.2018.10.008. View

11.

Sun J, Ahn M, Choi Y, Ahn J, Park K . Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer. 2013; 82(2):294-8. DOI: 10.1016/j.lungcan.2013.08.023. View

12.

Meddeb R, Pisareva E, Thierry A . Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin Chem. 2019; 65(5):623-633. DOI: 10.1373/clinchem.2018.298323. View

13.

Sorensen B, Wu L, Wei W, Tsai J, Weber B, Nexo E . Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014; 120(24):3896-901. PMC: 4303984. DOI: 10.1002/cncr.28964. View

14.

Jenkins S, Yang J, Ramalingam S, Yu K, Patel S, Weston S . Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017; 12(7):1061-1070. DOI: 10.1016/j.jtho.2017.04.003. View

15.

Papadimitrakopoulou V, Han J, Ahn M, Ramalingam S, Delmonte A, Hsia T . Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2019; 126(2):373-380. DOI: 10.1002/cncr.32503. View

16.

Wu J, Hu S, Zhang L, Xin J, Sun C, Wang L . Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics. 2020; 10(10):4544-4556. PMC: 7150480. DOI: 10.7150/thno.40532. View

17.

Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E . Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. J Thorac Oncol. 2019; 15(3):383-391. DOI: 10.1016/j.jtho.2019.11.024. View

18.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

19.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

20.

Liu L, Lin F, Ma X, Chen Z, Yu J . Tumor-educated platelet as liquid biopsy in lung cancer patients. Crit Rev Oncol Hematol. 2020; 146:102863. DOI: 10.1016/j.critrevonc.2020.102863. View